PhaseBio Pharmaceuticals Funding: $168M Raised, Series D
PhaseBio Pharmaceuticals is a Biotech company based in Dover, Delaware. It has raised $168M in total funding. Latest round: Series D.
PhaseBio Pharmaceuticals funding overview
PhaseBio Pharmaceuticals is a Biotech company based in Dover, Delaware. PhaseBio Pharmaceuticals has raised $168M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series D announced in January 2020. The round record for PhaseBio Pharmaceuticals runs through 2020; nothing later has been disclosed. Investors on record include SFJ Pharmaceuticals, AstraZeneca PLC, New Enterprise Associates, Hatteras Venture Partners, Johnson & Johnson Innovation, Pappas Capital and 4 others. 10 distinct backers are named across the disclosed rounds.
PhaseBio Pharmaceuticals at a glance
Total raised
$168M
Latest round
Series D
Latest round date
January 2020
Industry
Biotech
Headquarters
Dover, Delaware
Notable investors
SFJ Pharmaceuticals, AstraZeneca PLC, New Enterprise Associates, Hatteras Venture Partners, Johnson & Johnson Innovation, Pappas Capital, NYBC Ventures, Sanofi Ventures
Frequently asked about PhaseBio Pharmaceuticals funding
How much has PhaseBio Pharmaceuticals raised?
PhaseBio Pharmaceuticals has raised $168M in total disclosed funding across the rounds on record.
Who has invested in PhaseBio Pharmaceuticals?
SFJ Pharmaceuticals, AstraZeneca PLC, New Enterprise Associates, Hatteras Venture Partners, Johnson & Johnson Innovation, Pappas Capital are named among the investors backing PhaseBio Pharmaceuticals.
What was the latest PhaseBio Pharmaceuticals funding round?
The most recent disclosed round is a Series D, announced in January 2020.
Where is PhaseBio Pharmaceuticals based?
PhaseBio Pharmaceuticals is based in Dover, Delaware.
What sector does PhaseBio Pharmaceuticals operate in?
PhaseBio Pharmaceuticals is tracked under Biotech from Dover, Delaware, with $168M in disclosed funding.
When did PhaseBio Pharmaceuticals last raise?
The last disclosed PhaseBio Pharmaceuticals round closed in January 2020 at Series D.
Totals shown for PhaseBio Pharmaceuticals aggregate every disclosed round on file. To see how that compares, browse the Biotech companies in Dover and the investors behind them below.
Companies related to PhaseBio Pharmaceuticals (25)
